{"id":1301,"date":"2026-08-02T23:00:43","date_gmt":"2026-08-02T23:00:43","guid":{"rendered":"https:\/\/everlong.mediablizz.com\/?post_type=product&#038;p=1301"},"modified":"2026-08-02T23:01:28","modified_gmt":"2026-08-02T23:01:28","slug":"ipamorelin-10mg","status":"publish","type":"product","link":"https:\/\/everlong.mediablizz.com\/index.php\/product\/ipamorelin-10mg\/","title":{"rendered":"IPAMORELIN &#8211; 10MG"},"content":{"rendered":"<p><strong>pamorelin is a synthetic pentapeptide selective ghrelin \/ growth hormone secretagogue receptor (GHS-R1a) agonist, originally developed by Novo Nordisk in the late 1990s as a research compound. The peptide consists of five amino acids with two non-natural residues (Aib at position 1, D-2-naphthylalanine at position 3) designed to enhance receptor selectivity and metabolic stability. Ipamorelin is studied as one of the most selective GHS-R1a agonists characterized in research literature, reportedly stimulating endogenous growth hormone release without significant effects on cortisol, prolactin, ACTH, or aldosterone secretion \u2014 a selectivity profile that distinguishes it from earlier-generation GH secretagogues such as GHRP-6 and hexarelin. The compound is investigated in preclinical research for somatotropic axis pharmacology, GH release dynamics, and receptor selectivity studies, and is frequently paired with GHRH analogs (CJC-1295 No DAC, tesamorelin, sermorelin) in combined-pathway research protocols.<\/strong><\/p>\n<h4><strong>Benefits (Research Focus)<\/strong><\/h4>\n<p><strong>\u2022 Selective GHS-R1a agonism \u2014 studied as a highly selective ghrelin receptor agonist with minimal off-target receptor activity<\/strong><\/p>\n<p><strong>\u2022 GH release research \u2014 investigated for endogenous growth hormone release from pituitary somatotropes<\/strong><\/p>\n<p><strong>\u2022 Hormone selectivity \u2014 explored for reported minimal effects on cortisol, prolactin, ACTH, and aldosterone vs. other GH secretagogues<\/strong><\/p>\n<p><strong>\u2022 IGF-1 axis signaling \u2014 examined for downstream hepatic IGF-1 production and somatotropic endpoints<\/strong><\/p>\n<p><strong>\u2022 Combination pharmacology \u2014 researched alongside GHRH analogs (CJC-1295, tesamorelin) for paired pathway studies<\/strong><\/p>\n<h4><strong>\u26a0\ufe0f Disclaimer<\/strong><\/h4>\n<ul>\n<li><strong>This product is intended for laboratory research use only.<\/strong><\/li>\n<li><strong>Not for human or veterinary use.<\/strong><\/li>\n<li><strong>Not approved for diagnostic, therapeutic, or medical applications.<\/strong><\/li>\n<li><strong>Handle using appropriate laboratory safety procedures and personal protective equipment.<\/strong><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>pamorelin is a synthetic pentapeptide selective ghrelin \/ growth hormone secretagogue receptor (GHS-R1a) agonist, originally developed by Novo Nordisk in the late 1990s as a research compound. The peptide consists of five amino acids with two non-natural residues (Aib at position 1, D-2-naphthylalanine at position 3) designed to enhance receptor selectivity and metabolic stability. Ipamorelin [&hellip;]<\/p>\n","protected":false},"featured_media":1135,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[21,19],"product_tag":[72,60,73,94,75,74],"class_list":["post-1301","product","type-product","status-publish","has-post-thumbnail","product_cat-gh_secretagogue","product_cat-recovery","product_tag-cjc","product_tag-fat-lypolosis","product_tag-gh-secretagogue","product_tag-ghrelin","product_tag-ghrh","product_tag-growth-hormone","first","instock","taxable","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product\/1301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/comments?post=1301"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/media\/1135"}],"wp:attachment":[{"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/media?parent=1301"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product_brand?post=1301"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product_cat?post=1301"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product_tag?post=1301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}